SOUTH SAN FRANCISCO, Calif., May 17, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced an upcoming poster presentation for its lead product candidate, CX-072, a PD-L1 targeting Probody therapeutic for the treatment of cancer, at the American Society of Clinical Oncology Annual Meeting from June 2-6, 2017 in Chicago, Illinois. 

“The occurrence of immune-related adverse events is emerging as the Achilles’ heel of cancer immunotherapy,” said Rachel W. Humphrey, M.D., chief medical officer of CytomX Therapeutics. “Our recently initiated Phase 1/2 clinical trial, part of our umbrella PROCLAIM program, is investigating the potential of our differentiated, anti-PD-L1 Probody therapeutic, CX-072, to reduce overactivation of the immune system outside of the tumor, while remaining active as a single-agent and in combination therapy.  This poster presentation at ASCO will review the design and objectives of this ongoing study.”

Abstract Information

Title:PROCLAIM-001: A first-in-human trial to assess tolerability of the protease-activatable anti-PD-L1 Probody CX-072 in solid tumors and lymphomas
Author:Alexander I. Spira, M.D., Ph.D., F.A.C.P., Medical Oncologist and Director, Virginia Cancer Specialists Research Institute and Oncology Research
Session:Developmental Therapeutics—Immunotherapy
Date:Monday, June 5, 2017
Time:8:00 a.m. - 11:30 a.m.
Location:Hall A

About the PROCLAIM-CX-072 Trial
PROCLAIM-CX-072 is the first clinical trial under the international umbrella program, PROCLAIM. The trial is an open-label, dose-finding Phase 1/2 study evaluating CX-072 as monotherapy and in combination with Yervoy® (ipilimumab) or Zelboraf®(vemurafenib). As part of the study, CytomX aims to achieve three goals as part of the PROCLAIM-072 clinical trial:

  • Tolerability: Demonstrate that CX-072 is well tolerated in patients and potentially improves safety, particularly in the combination setting.
  • Anti-cancer activity: Demonstrate initial evidence of CX-072’s anti-cancer activity as monotherapy and in combination.
  • Translational program and Probody platform proof-of-concept: Explore mechanistic aspects of Probody activity in patients as observed in preclinical studies.

More information about the trial is available at

About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. The Company uses its platform to create proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and develop first-in-class cancer therapeutics against difficult-to-drug targets, such as CD166. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The Company’s lead program, CX-072, a wholly-owned PD-L1-targeting Probody therapeutic, is being evaluated in a Phase 1/2 study. CX-072 is part of PROCLAIM (Probody Clinical Assessment In Man), an international umbrella clinical trial program that provides clinical trial sites with access to the Company’s novel therapies under one central protocol. The trial initiation for CX-2009, a first-in-class Probody drug conjugate targeting the highly expressed tumor antigen, CD166, is expected mid-2017. In addition to its proprietary programs, CytomX is collaborating with strategic partners, including AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit or follow us on Twitter. 

CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential efficacy of CytomX’s product candidates, the Company’s ability to develop and advance product candidates into and successfully complete clinical trials, including the Company’s Phase 1/2 clinical trial of CX-072 and the timing of any future clinical trials. CX-072 is in the initial stages of clinical development, we have filed an IND for CX-2009, and our other product candidates are currently in preclinical development. The process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties. Applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in the Company’s Annual Report on Form 10-Q filed with the SEC on May 5, 2017. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

Media Contact: 
Canale Communications
Ian Stone

Investor Contact:
Trout Group
Elizabeth Broader